Sebela Ireland Ltd patents expiration
1. Brisdelle patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5874447 | SEBELA IRELAND LTD | 4-Phenylpiperidine compounds for treating depression |
Jun, 2017
(6 years ago) | |
| US7598271 | SEBELA IRELAND LTD | Crystalline paroxetine methane sulfonate |
May, 2025
(1 year, 5 days from now) | |
| US8946251 | SEBELA IRELAND LTD | Method of treating thermoregulatory dysfunction with paroxetine |
Aug, 2026
(2 years from now) | |
| US8658663 | SEBELA IRELAND LTD | Method of treating thermoregulatory disfunction with paroxetine |
Apr, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9393237 | SEBELA IRELAND LTD | Method of treating thermoregulatory dysfunction with paroxetine |
Aug, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 28, 2016 |
Drugs and Companies using PAROXETINE MESYLATE ingredient
Market Authorisation Date: 28 June, 2013
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: CAPSULE;ORAL
BRISDELLE family patents
2. Lotronex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5360800 | SEBELA IRELAND LTD | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives |
Jan, 2013
(11 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6284770 | SEBELA IRELAND LTD | Medicaments for the treatment of non-constipated female irritable bowel syndrome |
Oct, 2018
(5 years ago) | |
Drugs and Companies using ALOSETRON HYDROCHLORIDE ingredient
Market Authorisation Date: 23 December, 2003
Treatment: For women with severe diarrhea-predominant irritable bowel syndrome (ibs)
Dosage: TABLET;ORAL
LOTRONEX family patents
3. Naftin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778365 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US9161914 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US10729667 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US10166206 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US10166205 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US10695303 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 27, 2016 |
Drugs and Companies using NAFTIFINE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 June, 2013
Treatment: Treatment of fungal infections
Dosage: GEL;TOPICAL
NAFTIN family patents
4. Onmel patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8591948 | SEBELA IRELAND LTD | Antifungal compositions with improved bioavailability |
May, 2017
(6 years ago) | |
| US7081255 | SEBELA IRELAND LTD | Antifungal compositions with improved bioavailability |
May, 2017
(6 years ago) | |
| US6509038 | SEBELA IRELAND LTD | Antifungal compositions with improved bioavailability |
May, 2017
(6 years ago) | |
| US8486456 | SEBELA IRELAND LTD | Itraconazole compositions with improved bioavailability |
Oct, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 29, 2013 |
Drugs and Companies using ITRACONAZOLE ingredient
Market Authorisation Date: 29 April, 2010
Treatment: Onychomycosis of the toenail caused by tricophyton rubrum or trichophyton mentagrophytes, once daily use for 12 consecutive weeks
Dosage: TABLET;ORAL
ONMEL family patents
5. Pexeva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7598271 | SEBELA IRELAND LTD | Crystalline paroxetine methane sulfonate |
May, 2025
(1 year, 5 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5874447 | SEBELA IRELAND LTD | 4-Phenylpiperidine compounds for treating depression |
Jun, 2017
(6 years ago) | |
Drugs and Companies using PAROXETINE MESYLATE ingredient
Market Authorisation Date: 03 July, 2003
Treatment: Depression
Dosage: TABLET;ORAL
PEXEVA family patents